Immunotherapy in Treating Patients With Stage III-IV Skin Cancer
Research Question:
How does immunotherapy with pembrolizumab work before and after surgery in treating
patients with stage III-IV high-risk melanoma (skin cancer)?
Basic Study Information
Purpose:
This phase II trial studies how pembrolizumab works before and after surgery in treating
patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies,
such as pembrolizumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab
before and after surgery may work better in treating melanoma.
Location: University of Rochester Medical Center
Study Reference #: CMEL19154
Lead Researcher (Principal Investigator)
Lead Researcher:
Adrienne Victor
Study Contact Information
Study Coordinator: Park Bogan
Phone: (585) 276-4415
Email: Park_Bogan@URMC.Rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search